Samphire Neuroscience raises $5M Seed for neurotech wearable targeting menstrual health
Summary
Samphire Neuroscience has raised $5 million in seed funding led by Inventure VC with participation from Fortify Ventures. The company, which has offices in Australia and the UK, developed Nettle, a CE-certified headband device that uses transcranial direct current stimulation (tDCS) to address mental and physical symptoms associated with menstruation, including premenstrual dysphoric disorder (PMDD).
Why it matters
Samphire is tackling a massive unmet need affecting an estimated 190 million people globally who live with chronic menstrual conditions. Nettle sold out twice during its pre-launch phase, demonstrating strong market demand for neurotechnology solutions in women's health. Clinical evidence showed symptom relief for pain, mood swings, and brain fog within one month of use.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial